Filing Flows

Filing Flows › Companies › AbCellera Biologics › Cash flow

AbCellera Biologics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$23.8M in Q2 2026 · −$120M over twelve months

Operating cash flow$25.9M
Capital spending−$2.1M
Free cash flow+$23.8M

Analysis

In Q2 2026, AbCellera Biologics generated $25.9M of operating cash flow and spent $2.1M on capital projects, leaving free cash flow of $23.8M. That is $69.6M more than in Q2 2025 (−$45.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$94.9M; the largest uses were operating cash flow ($94.9M), capital spending ($24.7M); besides operations, cash came from other investing ($123M), other financing ($25.1M); the cash balance rose by $27.3M.

Operating cash flow was $25.9M against net income of −$55.4M. The largest differences: deferred revenue +$52.2M, stock-based pay +$12.3M, payables −$7.2M.

Free cash flow

AbCellera Biologics: free cash flow by quarterAbCellera Biologics: free cash flow by quarter−$47.4MQ3 2024−$23.6MQ4 2024−$22.2MQ1 2025−$45.8MQ2 2025−$61.5MQ3 2025−$44.6MQ4 2025−$37.4MQ1 2026$23.8MQ2 2026
Operating cash flow less capital spending.
AbCellera Biologics: operating cash flow against capital spendingAbCellera Biologics: operating cash flow against capital spendingOperating cash flowCapital spending−$28.9M$18.5MQ3 2024−$8.0M$15.6MQ4 2024−$11.6M$10.6MQ1 2025−$32.4M$13.4MQ2 2025−$52.6M$8.9MQ3 2025−$34.7M$9.8MQ4 2025−$33.5M$3.8MQ1 2026$25.9M$2.1MQ2 2026
Latest (Q2 2026): Operating cash flow $25.9M, Capital spending $2.1M.

Capital allocation, year by year

AbCellera Biologics: where the cash came from (up) and went (down), by fiscal yearAbCellera Biologics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow $245MFY2021: Net borrowing −$951KFY2021: Shares issued $4.6MFY2021: Capital spending −$58.5MFY2021: Acquisitions −$11.5M$249MFY2021FY2022: Operating cash flow $277MFY2022: Capital spending −$70.7M$277MFY2022FY2023: Operating cash flow −$43.9MFY2023: Capital spending −$76.9MFY2023FY2024: Operating cash flow −$109MFY2024: Capital spending −$78.4MFY2024FY2025: Operating cash flow −$131MFY2025: Capital spending −$42.8MFY2025
Over these 5 years operating cash flow totalled $238M; the largest uses were capital spending ($327M) and operating cash flow ($284M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$120M
Debtnone
Net cash$120M
Cash runway12 months

AbCellera Biologics is burning cash: its operations consume cash, a free cash flow of −$120M a year at the current rate against $120M of cash and investments: a runway of about 12 months before any new financing.

Where the cash came from and went

AbCellera Biologics: sources (+) and uses (−) of cash, Q2 2026AbCellera Biologics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)−$43.2MOperating cash flow$25.9MOther investing$13.5MOther financing$6.4MCapital spending−$2.1MExchange rates−$430K
AbCellera Biologics: sources (+) and uses (−) of cash, TTM to Q2 2026AbCellera Biologics: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$123MOperating cash flow−$94.9MCash drawn (+) / kept (−)−$27.3MOther financing$25.1MCapital spending−$24.7MExchange rates−$722K

From profit to cash

AbCellera Biologics: net income to operating cash flow, Q2 2026AbCellera Biologics: net income to operating cash flow, Q2 2026Net income−$55.4MDepreciation & amortization$7.0MStock-based pay$12.3MOther non-cash$4.6MPayables−$7.2MDeferred revenue$52.2MPrepaid and other assets$3.6MOperating cash flow$25.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$25.9M−$2.1M——−$43.2M$23.8M
Q1 2026−$33.5M−$3.8M——$51.5M−$37.4M
Q4 2025−$34.7M−$9.8M——−$44.8M−$44.6M
Q3 2025−$52.6M−$8.9M——$9.3M−$61.5M
Q2 2025−$32.4M−$13.4M——$66.8M−$45.8M
Q1 2025−$11.6M−$10.6M——−$2.9M−$22.2M
Q4 2024−$8.0M−$15.6M——−$29.7M−$23.6M
Q3 2024−$28.9M−$18.5M$3.1M$227K$21.7M−$47.4M

AbCellera Biologics: income statement and cash flow

AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year). The chart follows the revenue to costs, profit and cash.

AbCellera Biologics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.